Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.
暂无分享,去创建一个
John W. Park | D. Drummond | C. Noble | M. Hayes | D. Kirpotin | Daryl C Drummond | John W Park | Dmitri B Kirpotin | Charles O Noble | Mark E Hayes
[1] D. Lasič,et al. Liposomes: From Physics to Applications , 1993 .
[2] A. Chanan-Khan,et al. Bortezomib in combination with pegylated liposomal doxorubicin for the treatment of multiple myeloma. , 2007, Clinical lymphoma & myeloma.
[3] M. Dewhirst,et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. , 2000, Cancer research.
[4] M. Bally,et al. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. , 1997, Biochimica et biophysica acta.
[5] W. Hong,et al. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] L. Keus,et al. Feasibility, Phase I, and Pharmacological Study of Aerosolized Liposomal 9‐Nitro‐20(S)‐Camptothecin in Patients with Advanced Malignancies in the Lungs , 2000 .
[7] M. Bally,et al. Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice , 2006, Molecular Cancer Therapeutics.
[8] A. Janoff,et al. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts , 1997, International journal of cancer.
[9] M. Zignani,et al. Current status of pH-sensitive liposomes in drug delivery. , 2000, Progress in lipid research.
[10] Theresa M Allen,et al. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. , 2004, Biochimica et biophysica acta.
[11] T. Sonobe,et al. Liposomalization of SN-38 as active metabolite of CPT-11. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[12] M. Bally,et al. The presence of GM1 in liposomes with entrapped doxorubicin does not prevent RES blockade. , 1993, Biochimica et biophysica acta.
[13] T. Chen,et al. Alkylated derivatives of poly(ethylacrylic acid) can be inserted into preformed liposomes and trigger pH-dependent intracellular delivery of liposomal contents , 2004, Molecular membrane biology.
[14] K. Edwards,et al. An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[15] F. Szoka,et al. Cholesterol phosphate derivatives: synthesis and incorporation into a phosphatase and calcium-sensitive triggered release liposome. , 1998, Bioconjugate chemistry.
[16] D. Tzemach,et al. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[17] A. Malik,et al. Regulation of vascular endothelial barrier function. , 1994, The American journal of physiology.
[18] P. Cullis,et al. The bilayer stabilizing role of sphingomyelin in the presence of cholesterol: a 31P NMR study. , 1980, Biochimica et biophysica acta.
[19] Anitha Thomas,et al. Transition Metal-Mediated Liposomal Encapsulation of Irinotecan (CPT-11) Stabilizes the Drug in the Therapeutically Active Lactone Conformation , 2006, Pharmaceutical Research.
[20] Joel A Swanson,et al. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. , 2003, Advanced drug delivery reviews.
[21] M. Bally,et al. Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. , 2002, Biochimica et biophysica acta.
[22] Uchiyama,et al. The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. , 1999, Advanced drug delivery reviews.
[23] M. Bally,et al. The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations. , 2005, Current drug delivery.
[24] Samuel Zalipsky,et al. Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface‐grafted poly(ethylene glycol) , 1996, FEBS letters.
[25] F. Szoka,et al. Chemical approaches to triggerable lipid vesicles for drug and gene delivery. , 2003, Accounts of chemical research.
[26] G. Scambia,et al. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] A. Judge,et al. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[28] M. Bally,et al. A Comparison of Liposomal Formulations of Doxorubicin with Drug Administered in Free Form , 2001, Drug safety.
[29] Michael Hawkins,et al. Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol) , 2005, Clinical Cancer Research.
[30] K. Kono,et al. Thermosensitive polymer-modified liposomes. , 2001, Advanced drug delivery reviews.
[31] L. Leserman,et al. Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[32] F. Szoka,et al. Low‐pH‐sensitive poly(ethylene glycol) (PEG)‐stabilized plasmid nanolipoparticles: effects of PEG chain length, lipid composition and assembly conditions on gene delivery , 2005, The journal of gene medicine.
[33] M. Yatvin,et al. pH-sensitive liposomes: possible clinical implications. , 1980, Science.
[34] R K Jain,et al. Transport in lymphatic capillaries. I. Macroscopic measurements using residence time distribution theory. , 1996, The American journal of physiology.
[35] R. B. Campbell,et al. Influence of cationic lipids on the stability and membrane properties of paclitaxel-containing liposomes. , 2001, Journal of pharmaceutical sciences.
[36] F. Muggia,et al. Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] R. Straubinger,et al. Pharmacokinetics of paclitaxel-containing liposomes in rats , 2003, AAPS PharmSci.
[38] Simon C Watkins,et al. Dynamic changes in the characteristics of cationic lipidic vectors after exposure to mouse serum: implications for intravenous lipofection , 1999, Gene Therapy.
[39] D. Alberts,et al. Role of pegylated liposomal doxorubicin in ovarian cancer. , 2005, Gynecologic oncology.
[40] N. Harbeck,et al. Reduced Incidence of Severe Palmar-Plantar Erythrodysesthesia and Mucositis in a Prospective Multicenter Phase II Trial with Pegylated Liposomal Doxorubicin at 40 mg/m2 Every 4 Weeks in Previously Treated Patients with Metastatic Breast Cancer , 2006, Oncology.
[41] Corrie Lynn Messerer,et al. Liposomal Irinotecan , 2004, Clinical Cancer Research.
[42] F. Szoka,et al. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating , 2005, Brain Research.
[43] M. Dewhirst,et al. Preferential extravasation and accumulation of liposomal vincristine in tumor comparing to normal tissue enhances antitumor activity , 2006, Cancer Chemotherapy and Pharmacology.
[44] D. Papahadjopoulos,et al. Permeability properties of phospholipid membranes: effect of cholesterol and temperature. , 1972, Biochimica et biophysica acta.
[45] M. Bally,et al. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. , 1990, Biochimica et biophysica acta.
[46] G. Scherphof,et al. UPTAKE AND PROCESSING OF IMMUNOGLOBULIN-COATED LIPOSOMES BY SUBPOPULATIONS OF RAT-LIVER MACROPHAGES , 1988 .
[47] R. Straubinger,et al. Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia. , 1996, Cancer letters.
[48] L. Huang,et al. Structural and functional comparisons of pH-sensitive liposomes composed of phosphatidylethanolamine and three different diacylsuccinylglycerols. , 1990, Biochimica et biophysica acta.
[49] Ulrik B Nielsen,et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[50] M. Bally,et al. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. , 1990, Chemistry and physics of lipids.
[51] T. Allen,et al. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs. , 2004, Journal of the National Cancer Institute.
[52] Yu Zhou,et al. Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. , 2007, Journal of molecular biology.
[53] A. Tall,et al. Interaction between unilamellar egg yolk lecithin vesicles and human high density lipoprotein. , 1979, Biochemistry.
[54] W. Guo,et al. A simple and sensitive LC/MS/MS assay for 7-ethyl-10-hydroxycamptothecin (SN-38) in mouse plasma and tissues: application to pharmacokinetic study of liposome entrapped SN-38 (LE-SN38). , 2005, Journal of pharmaceutical and biomedical analysis.
[55] P. Cullis,et al. Anomalous solubility behavior of the antibiotic ciprofloxacin encapsulated in liposomes: a 1H-NMR study. , 1998, Biochimica et biophysica acta.
[56] D. Stuart,et al. A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability. , 2000, Biochimica et biophysica acta.
[57] T. Ishida,et al. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[58] T. Ishida,et al. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[59] Xiao-ling Fang,et al. Biodistribution in mice and severity of damage in rat lungs following pulmonary delivery of 9-nitrocamptothecin liposomes. , 2008, Pulmonary pharmacology & therapeutics.
[60] S. Kennel,et al. Characterization of organ-specific immunoliposomes for delivery of 3′,5′-O-dipalmitoyl-5-fluoro-2′-deoxyuridine in a mouse lung-metastasis model , 2004, Cancer Chemotherapy and Pharmacology.
[61] T M Allen,et al. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. , 1991, Biochimica et biophysica acta.
[62] F M Muggia,et al. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. , 1998, Journal of the National Cancer Institute.
[63] F. Martin,et al. Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. , 1993, Cancer research.
[64] J. Slotte,et al. Membrane properties of D-erythro-N-acyl sphingomyelins and their corresponding dihydro species. , 2001, Biophysical journal.
[65] R K Jain,et al. Noninvasive measurement of interstitial pH profiles in normal and neoplastic tissue using fluorescence ratio imaging microscopy. , 1994, Cancer research.
[66] D. Liggitt,et al. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. , 1999, Journal of immunology.
[67] R. Jain,et al. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. , 1994, Cancer research.
[68] D. Borchman,et al. Conformational studies of sphingolipids by NMR spectroscopy , 2000 .
[69] M. Bally,et al. Copper-topotecan complexation mediates drug accumulation into liposomes. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[70] C. Benz,et al. Enhanced Pharmacodynamic and Antitumor Properties of a Histone Deacetylase Inhibitor Encapsulated in Liposomes or ErbB2-Targeted Immunoliposomes , 2005, Clinical Cancer Research.
[71] T. Allen,et al. Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. , 1989, Biochimica et biophysica acta.
[72] G. Schwartz,et al. Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] C. Benz,et al. Development of ligand-targeted liposomes for cancer therapy , 2004, Expert opinion on therapeutic targets.
[74] D. Ribatti,et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. , 2003, Cancer research.
[75] M. Dewhirst,et al. Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. , 1996, International journal of radiation oncology, biology, physics.
[76] V. Grégoire,et al. Modulation of the tumor vasculature functionality by ionizing radiation accounts for tumor radiosensitization and promotes gene delivery , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[77] Susan O'Brien,et al. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia , 2006, Cancer.
[78] Jennifer I. Hare,et al. Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. , 2006, Anti-cancer agents in medicinal chemistry.
[79] Kamps,et al. Receptor versus non-receptor mediated clearance of liposomes. , 1998, Advanced drug delivery reviews.
[80] Yechezkel Barenholz,et al. Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs , 1993, Pharmaceutical Research.
[81] F. Dosio,et al. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[82] D. Colagiovanni,et al. Pharmacokinetics , Safety , and Efficacy of a Liposome Encapsulated Thymidylate Synthase Inhibitor , OSI-7904 L [ ( S )-2-[ 5-[ ( 1 , 2-Dihydro-3-methyl-1-oxobenzo [ f ] quinazolin-9-yl ) methyl ] amino-1-oxo-2-isoindolynl ]-glutaric Acid ] in Mice , 2004 .
[83] D. Tzemach,et al. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals , 1997 .
[84] W. Hong,et al. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[85] R. Perez-soler,et al. In vivo antitumor activity of cis-bis-neodecanoato-trans- R,R-l,2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes , 2009, Cancer Chemotherapy and Pharmacology.
[86] M. Bally,et al. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. , 1989, Cancer research.
[87] M. Bally,et al. Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes , 2004, Cancer Chemotherapy and Pharmacology.
[88] L. Gianni,et al. Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.
[89] F. Muggia,et al. Phase III data on Caelyx in ovarian cancer. , 2001, European journal of cancer.
[90] S. Stewart,et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] R. Straubinger,et al. Novel Taxol Formulations: Preparation and Characterization of Taxol-Containing Liposomes , 1994, Pharmaceutical Research.
[92] J. Schellens,et al. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin , 2002, Cancer Chemotherapy and Pharmacology.
[93] L. Matherly,et al. Human reduced folate carrier: translation of basic biology to cancer etiology and therapy , 2007, Cancer and Metastasis Reviews.
[94] Xin Huang,et al. A Bacterial Protein Enhances the Release and Efficacy of Liposomal Cancer Drugs , 2006, Science.
[95] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[96] P. Cullis,et al. Stabilized Plasmid–Lipid Particles: Pharmacokinetics and Plasmid Delivery to Distal Tumors following Intravenous Injection , 2000, Journal of drug targeting.
[97] F. Martin,et al. Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts. , 1996, Cancer Research.
[98] M. Bally,et al. Kupffer cells do not play a role in governing the efficacy of liposomal mitoxantrone used to treat a tumor model designed to assess drug delivery to liver. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[99] A. Bedikian,et al. Pharmacokinetics and Urinary Excretion of Vincristine Sulfate Liposomes Injection in Metastatic Melanoma Patients , 2006, Journal of clinical pharmacology.
[100] P. van Hoogevest,et al. Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[101] S. Simões,et al. Sterically stabilized ph-sensitive liposomes. , 2004, Methods in enzymology.
[102] P. Meers,et al. Enzyme-activated targeting of liposomes. , 2001, Advanced drug delivery reviews.
[103] Y. Barenholz,et al. Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. , 1986, Journal of the National Cancer Institute.
[104] Theresa M Allen,et al. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. , 2002, Cancer research.
[105] Xin Yu Wang,et al. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[106] T M Allen,et al. Liver pathology accompanying chronic liposome administration in mouse. , 1985, Research communications in chemical pathology and pharmacology.
[107] David H. Thompson,et al. Cytosolic drug delivery using pH- and light-sensitive liposomes. , 1999, Advanced drug delivery reviews.
[108] D. Baccanari,et al. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[109] Y. Barenholz,et al. Characterization of sterically stabilized cisplatin liposomes by nuclear magnetic resonance. , 2001, Biochimica et biophysica acta.
[110] M. Johnston,et al. Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. , 2006, Biochimica et biophysica acta.
[111] A. Gabizon,et al. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. , 1990, Cancer research.
[112] B. Bondurant,et al. Rapid release of liposomal contents upon photoinitiated destabilization with UV exposure. , 2003, Biochimica et biophysica acta.
[113] Y. Assaraf. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. , 2006, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[114] D. Carbonaro,et al. Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. , 2005, Anticancer research.
[115] S. Simões,et al. Sterically Stabilized pH-sensitive Liposomes , 1997, The Journal of Biological Chemistry.
[116] F. Szoka,et al. Thiocholesterol-based lipids for ordered assembly of bioresponsive gene carriers. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[117] M S Newman,et al. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. , 1997, Biochimica et biophysica acta.
[118] M. Hope,et al. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles. , 2001, The Journal of pharmacology and experimental therapeutics.
[119] M. Newman,et al. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice , 1999, Cancer Chemotherapy and Pharmacology.
[120] M. Bally,et al. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. , 1985, Biochimica et biophysica acta.
[121] P. Stauffer,et al. Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. , 1994, Cancer research.
[122] J. Northrop,et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[123] P. Cullis,et al. Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behaviour in vivo. , 1998, Advanced drug delivery reviews.
[124] P. Cullis,et al. Separation of large unilamellar liposomes from blood components by a spin column procedure: towards identifying plasma proteins which mediate liposome clearance in vivo. , 1991, Biochimica et biophysica acta.
[125] D. Tzemach,et al. Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. , 1996, Journal of drug targeting.
[126] G. Pond,et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[127] Norbert Maurer,et al. Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin. , 2007, Biochimica et biophysica acta.
[128] F. Chang,et al. Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation , 2002, Anti-cancer drugs.
[129] P. Steerenberg,et al. Release of doxorubicin from peritoneal macrophages exposed in vivo to doxorubicin-containing liposomes. , 1988, Biochimica et biophysica acta.
[130] C. Shapiro,et al. Cardiac safety of liposomal anthracyclines. , 2004, Seminars in oncology.
[131] Marc Dellian,et al. Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[132] I. Vorobyov,et al. Conformational studies of sphingolipids by NMR spectroscopy. II. Sphingomyelin. , 2000, Biochimica et biophysica acta.
[133] D. Papahadjopoulos,et al. Role of cholesterol in membranes. Effects on phospholipid-protein interactions, membrane permeability and enzymatic activity. , 1973, Biochimica et biophysica acta.
[134] J Verweij,et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. , 2001, European journal of cancer.
[135] P. Cullis,et al. Influence of dose on liposome clearance: critical role of blood proteins. , 1996, Biochimica et biophysica acta.
[136] M. Kool,et al. A family of drug transporters: the multidrug resistance-associated proteins. , 2000, Journal of the National Cancer Institute.
[137] G. Storm,et al. Liposomes to target the lymphatics by subcutaneous administration. , 2001, Advanced drug delivery reviews.
[138] F. Szoka,et al. Efficiency of Cytoplasmic Delivery by pH-Sensitive Liposomes to Cells in Culture , 1990, Pharmaceutical Research.
[139] F. Martin,et al. Pharmacokinetics and antitumor activity of epirubicin encapsulated in long‐circulating liposomes incorporating a polyethylene glycol‐derivatized phospholipid , 1992, International journal of cancer.
[140] T. Andresen,et al. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. , 2005, Progress in lipid research.
[141] T. Ishida,et al. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[142] J. Zhang,et al. The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[143] T. E. Thompson,et al. Interaction of cholesterol with various glycerophospholipids and sphingomyelin. , 1990, Biochemistry.
[144] Ulrik B Nielsen,et al. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. , 2002, Biochimica et biophysica acta.
[145] M. Bally,et al. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. , 1997, The Journal of pharmacology and experimental therapeutics.
[146] D. V. Hoff,et al. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer , 2006, Cancer Chemotherapy and Pharmacology.
[147] M. Zeidel,et al. The relationship between membrane fluidity and permeabilities to water, solutes, ammonia, and protons , 1995, The Journal of general physiology.
[148] L. Mayer,et al. Determination of free and liposome-associated doxorubicin and vincristine levels in plasma under equilibrium conditions employing ultrafiltration techniques. , 1995, Analytical biochemistry.
[149] S. Mantripragada. A lipid based depot (DepoFoam technology) for sustained release drug delivery. , 2002, Progress in lipid research.
[150] S. Kawakami,et al. Physicochemical and pharmacokinetic characteristics of cationic liposomes. , 2006, Die Pharmazie.
[151] J H Senior,et al. Fate and behavior of liposomes in vivo: a review of controlling factors. , 1987, Critical reviews in therapeutic drug carrier systems.
[152] Y. Barenholz,et al. Gelation of liposome interior A novel method for drug encapsulation , 1992, FEBS letters.
[153] Theresa M. Allen,et al. Pharmacokinetics of long-circulating liposomes , 1995 .
[154] F. Fraternali,et al. Hydrogen-bonding propensities of sphingomyelin in solution and in a bilayer assembly: a molecular dynamics study. , 2003, Biophysical journal.
[155] M. Berger,et al. Distribution of Liposomes into Brain and Rat Brain Tumor Models by Convection-Enhanced Delivery Monitored with Magnetic Resonance Imaging , 2004, Cancer Research.
[156] Y. Barenholz,et al. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. , 1993, Biochimica et biophysica acta.
[157] R. Rietbroek,et al. Hyperthermia enhances tumor uptake and antitumor efficacy of thermostable liposomal daunorubicin in a rat solid tumor. , 1996, Cancer research.
[158] T. Zhang,et al. Liposome-anchored vascular endothelial growth factor aptamers. , 1998, Bioconjugate chemistry.
[159] K. Matthay,et al. Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. , 1992, Biochimica et biophysica acta.
[160] N. Van Rooijen,et al. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. , 1994, Biochimica et biophysica acta.
[161] D. Papahadjopoulos,et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. , 1999, Pharmacological reviews.
[162] M. Newman,et al. Pharmacokinetics, Biodistribution and Therapeutic Efficacy of Doxorubicin Encapsulated in Stealth® Liposomes (Doxil®) , 1994 .
[163] D. Mager,et al. Effect of Repetitive Administration of Doxorubicin-Containing Liposomes on Plasma Pharmacokinetics and Drug Biodistribution in a Rat Brain Tumor Model , 2005, Clinical Cancer Research.
[164] Theresa M Allen,et al. Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. , 2003, Biochimica et biophysica acta.
[165] M. Dewhirst,et al. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: Illustration of targeted delivery , 2004, Magnetic resonance in medicine.
[166] E. Chang,et al. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. , 2002, Molecular cancer therapeutics.
[167] P. Kramer,et al. Liposomal entrapment of floxuridine. , 1977, Journal of pharmaceutical sciences.
[168] J. Lehn,et al. The design of cationic lipids for gene delivery. , 2005, Current pharmaceutical design.
[169] P. Cullis,et al. Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles. , 1994, Biochimica et biophysica acta.
[170] F. Szoka,et al. Lipid-based Nanoparticles for Nucleic Acid Delivery , 2007, Pharmaceutical Research.
[171] R. Jain,et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[172] Mark W Dewhirst,et al. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. , 2007, Journal of the National Cancer Institute.
[173] J. Correia,et al. Vinca alkaloid-induced tubulin spiral formation correlates with cytotoxicity in the leukemic L1210 cell line. , 2000, Biochemistry.
[174] C. Cass,et al. The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs , 2007, Cancer and Metastasis Reviews.
[175] R. Rifkin,et al. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma , 2006, Cancer.
[176] M. Bally,et al. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. , 2000, Cancer research.
[177] J. Schellens,et al. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma , 2004, Cancer Chemotherapy and Pharmacology.
[178] J. M. Smaby,et al. Cholesterol decreases the interfacial elasticity and detergent solubility of sphingomyelins. , 2001, Biochemistry.
[179] P. Ahl,et al. Elastase activated liposomal delivery to nucleated cells. , 1999, Biochimica et biophysica acta.
[180] M. Bally,et al. A two-step targeting approach for delivery of doxorubicin-loaded liposomes to tumour cells in vivo , 2004, Cancer Chemotherapy and Pharmacology.
[181] M. Dellian,et al. Neovascular targeting chemotherapy: Encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature , 2004, International journal of cancer.
[182] G. Gregoriadis,et al. The effect of lipid composition of small unilamellar liposomes containing melphalan and vincristine on drug clearance after injection into mice. , 1983, Biochemical pharmacology.
[183] L. Mayer,et al. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. , 2001, The Journal of pharmacology and experimental therapeutics.
[184] C. Benz,et al. Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery , 2006, Gene Therapy.
[185] Francis C Szoka,et al. Barriers to carrier mediated drug and gene delivery to brain tumors. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[186] L. Huang,et al. Some negatively charged phospholipid derivatives prolong the liposome circulation in vivo. , 1992, Biochimica et biophysica acta.
[187] P. Cullis,et al. Influence of cholesterol on the association of plasma proteins with liposomes. , 1996, Biochemistry.
[188] R. Zhou,et al. Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. , 2002, Cancer research.
[189] G. Scherphof,et al. Transfer and exchange of phospholipid between small unilamellar liposomes and rat plasma high density lipoproteins. Dependence on cholesterol content and phospholipid composition. , 1981, Biochimica et biophysica acta.
[190] M. Dewhirst,et al. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. , 2001, Advanced drug delivery reviews.
[191] J Szebeni,et al. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. , 2003, Progress in lipid research.
[192] S. Clerc,et al. Loading of amphipathic weak acids into liposomes in response to transmembrane calcium acetate gradients. , 1995, Biochimica et biophysica acta.
[193] M. Bally,et al. In Vitro and in Vivo Characterization of Doxorubicin and Vincristine Coencapsulated within Liposomes through Use of Transition Metal Ion Complexation and pH Gradient Loading , 2004, Clinical Cancer Research.
[194] R. Bankert,et al. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. , 2000, Cancer research.
[195] Vladimir P Torchilin,et al. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. , 2006, Annual review of biomedical engineering.
[196] J. Zhang,et al. Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[197] A. Spector,et al. Membrane cholesterol and phospholipid in consecutive concentric sections of human lenses. , 1985, Journal of lipid research.
[198] D. Tzemach,et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma , 2000, Cancer.
[199] A. Gabizon,et al. Liposome circulation time and tumor targeting: implications for cancer chemotherapy , 1995 .
[200] P. van Hoogevest,et al. Lipophilic Drug Transfer Between Liposomal and Biological Membranes: What Does It Mean for Parenteral and Oral Drug Delivery? , 2006, Journal of liposome research.
[201] M. Woodle,et al. Pharmacokinetics and anti‐tumor activity of vincristine encapsulated in sterically stabilized liposomes , 1995, International journal of cancer.
[202] Yechezkel Barenholz,et al. Pharmacokinetics of Pegylated Liposomal Doxorubicin , 2003, Clinical pharmacokinetics.
[203] D. Papahadjopoulos,et al. The introduction of poliovirus RNA into cells via lipid vesicles (liposomes) , 1979, Cell.
[204] P. Cullis,et al. Factors influencing uptake and retention of amino-containing drugs in large unilamellar vesicles exhibiting transmembrane pH gradients. , 1999, Biochimica et biophysica acta.
[205] F. Szoka,et al. Role of cholesterol in enhancing the antitumor activity of cytosine arabinoside entrapped in liposomes. , 1979, Cancer treatment reports.
[206] M. Newman,et al. Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs , 1999, Human & experimental toxicology.
[207] Theresa M Allen,et al. Advantages of liposomal delivery systems for anthracyclines. , 2004, Seminars in oncology.
[208] O. Kaalhus,et al. Radiation Improves the Distribution and Uptake of Liposomal Doxorubicin (Caelyx) in Human Osteosarcoma Xenografts , 2004, Cancer Research.
[209] K. Edwards,et al. Formation of drug-arylsulfonate complexes inside liposomes: a novel approach to improve drug retention. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[210] T. Allen. A study of phospholipid interactions between high-density lipoproteins and small unilamellar vesicles. , 1981, Biochimica et biophysica acta.
[211] Feng Liu,et al. Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. , 2005, Advanced drug delivery reviews.
[212] Perttu S. Niemelä,et al. Structure and dynamics of sphingomyelin bilayer: insight gained through systematic comparison to phosphatidylcholine. , 2004, Biophysical journal.
[213] D. Drummond,et al. Synthesis and characterization of N-acylated, pH-sensitive 'caged' aminophospholipids. , 1995, Chemistry and physics of lipids.
[214] K. Kono,et al. Novel gene delivery systems: complexes of fusigenic polymer-modified liposomes and lipoplexes , 2001, Gene Therapy.
[215] Matthias John,et al. RNAi-mediated gene silencing in non-human primates , 2006, Nature.
[216] T. Allen,et al. Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. , 1993, Biochimica et biophysica acta.
[217] M. Angst,et al. Pharmacology of Drugs Formulated with DepoFoam™ , 2006, Clinical pharmacokinetics.
[218] Bengt Rippe,et al. Glomerular filtration rate dependence of sieving of albumin and some neutral proteins in rat kidneys. , 2003, American journal of physiology. Renal physiology.
[219] M. Yessine,et al. Membrane-destabilizing polyanions: interaction with lipid bilayers and endosomal escape of biomacromolecules. , 2004, Advanced drug delivery reviews.
[220] J. Heyes,et al. Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. , 2005, Biochimica et biophysica acta.
[221] P. Cullis,et al. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. , 1992, The Journal of biological chemistry.
[222] R. Bittman,et al. Interaction of cholesterol with sphingomyelin in monolayers and vesicles. , 1994, Biochemistry.
[223] C. Mamot,et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. , 2005, Cancer research.
[224] M. Berger,et al. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. , 2006, Cancer research.
[225] Theresa M Allen,et al. Multiple Injections of Pegylated Liposomal Doxorubicin: Pharmacokinetics and Therapeutic Activity , 2003, Journal of Pharmacology and Experimental Therapeutics.
[226] W. Oyen,et al. Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose. , 2000, The Journal of pharmacology and experimental therapeutics.
[227] David H. Thompson,et al. Phototriggering of liposomal drug delivery systems. , 2001, Advanced drug delivery reviews.
[228] Christopher Poole,et al. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[229] M. Berger,et al. Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: Implications for local drug delivery , 2006, Journal of Neuroscience Methods.
[230] M. Hope,et al. Antibacterial Efficacy against an In Vivo Salmonella typhimurium Infection Model and Pharmacokinetics of a Liposomal Ciprofloxacin Formulation , 1998, Antimicrobial Agents and Chemotherapy.
[231] Imran Ahmad,et al. Development and characterization of a novel liposome-based formulation of SN-38. , 2004, International journal of pharmaceutics.
[232] F. Khuri,et al. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. , 2001, Lung cancer.
[233] M. Berger,et al. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. , 2006, Neuro-oncology.
[234] D. Thompson,et al. Acid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG-lipids. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[235] M A Fischl,et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[236] B. Haraldsson,et al. Glomerular size and charge selectivity in the rat as revealed by FITC-ficoll and albumin. , 2000, American journal of physiology. Renal physiology.
[237] S. Bhatia,et al. Enhancement of the in vivo circulation lifetime of L-alpha-distearoylphosphatidylcholine liposomes: importance of liposomal aggregation versus complement opsonization. , 1997, Biochimica et biophysica acta.
[238] H. D. Liggitt,et al. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery , 1997, Nature Biotechnology.
[239] A. Gabizon,et al. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. , 1989, Journal of the National Cancer Institute.
[240] P Berg,et al. Introduction of liposome-encapsulated SV40 DNA into cells. , 1980, The Journal of biological chemistry.
[241] M. Hope,et al. Immunogenicity and Rapid Blood Clearance of Liposomes Containing Polyethylene Glycol-Lipid Conjugates and Nucleic Acid , 2005, Journal of Pharmacology and Experimental Therapeutics.
[242] P. Cullis,et al. Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles. , 2007, International immunopharmacology.
[243] S. Haupt,et al. Drug targeting by surface cationization. , 2000, Critical reviews in therapeutic drug carrier systems.
[244] Francis C Szoka,et al. Low-pH-sensitive PEG-stabilized plasmid-lipid nanoparticles: preparation and characterization. , 2003, Bioconjugate chemistry.
[245] C. Verschraegen,et al. Clinical Evaluation of the Delivery and Safety of Aerosolized Liposomal 9-Nitro-20(S)-Camptothecin in Patients with Advanced Pulmonary Malignancies , 2004, Clinical Cancer Research.
[246] Joseph Kost,et al. Controlling liposomal drug release with low frequency ultrasound: mechanism and feasibility. , 2007, Langmuir : the ACS journal of surfaces and colloids.
[247] M. Bally,et al. Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity , 1999, Nature Biotechnology.
[248] D. McDonald,et al. Organ-specific endothelial cell uptake of cationic liposome-DNA complexes in mice. , 1997, The American journal of physiology.
[249] K. Edwards,et al. Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. , 2005, Journal of pharmaceutical sciences.
[250] E. C. Beuvery,et al. Comparison of four bifunctional reagents for coupling peptides to proteins and the effect of the three moieties on the immunogenicity of the conjugates. , 1989, Journal of immunological methods.
[251] M. Bally,et al. Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. , 1998, Biochimica et biophysica acta.
[252] M. Bally,et al. CHAPTER 4.2 – Designing therapeutically optimized liposomal anticancer delivery systems: Lessons from conventional liposomes , 1998 .
[253] J. Dijkstra,et al. Interaction of liposomes with Kupffer cells in vitro. , 1984, Experimental cell research.
[254] T M Allen,et al. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. , 1998, Cancer research.
[255] M. Bally,et al. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. , 1995, British Journal of Cancer.
[256] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[257] G. Kenner,et al. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. , 2007, Biochimica et biophysica acta.
[258] D. Papahadjopoulos,et al. Ultrastructural characterization of cationic liposome-DNA complexes showing enhanced stability in serum and high transfection activity in vivo. , 1998, Biochimica et biophysica acta.
[259] P. Cullis,et al. Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[260] G. Wood,et al. Targeting of the Antivascular Drug Combretastatin to Irradiated Tumors Results in Tumor Growth Delay , 2005, Pharmaceutical Research.
[261] Michael Hawkins,et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[262] T. Allen,et al. Ligand-targeted liposomal anticancer drugs. , 2003, Progress in lipid research.
[263] C. Brayton,et al. 9-NITROCAMPTOTHECIN LIPOSOME AEROSOL: LACK OF SUBACUTE TOXICITY IN DOGS , 2002, Inhalation toxicology.
[264] D Needham,et al. Elastic deformation and failure of lipid bilayer membranes containing cholesterol. , 1990, Biophysical journal.
[265] Y. Barenholz,et al. Targeted Delivery of Doxorubicin via Sterically Stabilized Immunoliposomes: Pharmacokinetics and Biodistribution in Tumor-bearing Mice , 1996, Pharmaceutical Research.
[266] H. Groen,et al. Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[267] H. Harashima,et al. Pharmacokinetic/pharmacodynamic modeling of antitumor agents encapsulated into liposomes. , 1999, Advanced drug delivery reviews.
[268] J. Drevs,et al. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study , 2004, Cancer Chemotherapy and Pharmacology.
[269] F. Dosio,et al. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[270] N Thatcher,et al. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer , 2006, British Journal of Cancer.
[271] T. Allen,et al. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. , 1991, Biochimica et biophysica acta.
[272] B. Tromberg,et al. Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue. , 1996, Cancer research.
[273] Theresa M. Allen,et al. Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors , 2005, Clinical Cancer Research.
[274] M. Bally,et al. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. , 2007, Biochimica et biophysica acta.
[275] E. Moase,et al. Improved Therapeutic Responses in a Xenograft Model of Human B Lymphoma (Namalwa) for Liposomal Vincristine versus Liposomal Doxorubicin Targeted via Anti-CD19 IgG2a or Fab′ Fragments , 2004, Clinical Cancer Research.
[276] U. Nielsen,et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.
[277] Keith Bowman,et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs , 2005, Nature Biotechnology.
[278] Vladimir P Torchilin,et al. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. , 2002, Cancer research.
[279] Theresa M Allen,et al. Anti-CD19-Targeted Liposomal Doxorubicin Improves the Therapeutic Efficacy in Murine B-Cell Lymphoma and Ameliorates the Toxicity of Liposomes with Varying Drug Release Rates , 2005, Clinical Cancer Research.
[280] T. Ishida,et al. Accelerated clearance of PEGylated liposomes in rats after repeated injections. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[281] A. Urtti,et al. Extracellular Glycosaminoglycans Modify Cellular Trafficking of Lipoplexes and Polyplexes* , 2001, The Journal of Biological Chemistry.
[282] M. Stuart,et al. Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. , 1995, Biochimica et biophysica acta.
[283] P. Uster,et al. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[284] G. Gregoriadis,et al. Stability of small unilamellar liposomes in serum and clearance from the circulation: the effect of the phospholipid and cholesterol components. , 1982, Life sciences.
[285] Philip S Low,et al. Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging , 2006, Proceedings of the National Academy of Sciences.
[286] M. Bally,et al. Liposomes with entrapped doxorubicin exhibit extended blood residence times. , 1990, Biochimica et biophysica acta.
[287] John W. Park,et al. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. , 2006, Cancer research.
[288] J. Leroux,et al. In vitro characterization of a novel polymeric-based pH-sensitive liposome system. , 2000, Biochimica et biophysica acta.
[289] J. Hagstrom,et al. pH-sensitive, cationic liposomes: A new synthetic virus-like vector , 1996, Nature Biotechnology.
[290] W. Guo,et al. Paclitaxel quantification in mouse plasma and tissues containing liposome-entrapped paclitaxel by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetics study. , 2005, Analytical biochemistry.
[291] M. Bally,et al. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). , 1997, The Journal of pharmacology and experimental therapeutics.
[292] S. Parker,et al. Tissue distribution of the cytofectin component of a plasmid-DNA/cationic lipid complex following intravenous administration in mice. , 1997, Human gene therapy.
[293] F. Szoka,et al. Cyclic amphipathic peptide-DNA complexes mediate high-efficiency transfection of adherent mammalian cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[294] Ryuta Saito,et al. Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain , 2005, Experimental Neurology.
[295] K. Mechtler,et al. Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. , 1996, Human gene therapy.
[296] C G Morgan,et al. Active Uptake of Drugs into Photosensitive Liposomes and Rapid Release on UV Photolysis¶ , 2000, Photochemistry and photobiology.
[297] D. Scherman,et al. Reducible cationic lipids for gene transfer. , 2001, The Biochemical journal.
[298] Paul R. Lockman,et al. Nanoparticle Surface Charges Alter Blood–Brain Barrier Integrity and Permeability , 2004, Journal of drug targeting.
[299] Dayan Ad. Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl). , 1996 .
[300] D. Ribatti,et al. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[301] F. Szoka,et al. pH-dependent fusion of phosphatidylcholine small vesicles. Induction by a synthetic amphipathic peptide. , 1988, The Journal of biological chemistry.
[302] P. Cullis,et al. Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients. , 1998, Biochimica et biophysica acta.
[303] F. Goñi,et al. Interaction of cholesterol with sphingomyelin in mixed membranes containing phosphatidylcholine, studied by spin-label ESR and IR spectroscopies. A possible stabilization of gel-phase sphingolipid domains by cholesterol. , 2001, Biochemistry.